Advancements in Surgical Intervention for Obstructive Sleep Apnea (Podcast)

Obstructive sleep apnea affects millions of people in the United States. Although continuous positive airway pressure (CPAP) remains the gold standard treatment, newer therapies – such as hypoglossal nerve stimulation – provide options for patients that can’t tolerate CPAP.

“I think it’s an exciting time right now for patients that are looking for alternative therapies for obstructive sleep apnea,” says Vaibhav Ramprasad, MD, an otolaryngologist – head and neck surgeon in at Cleveland Clinic who specializes in surgical sleep and snoring treatment. “While hypoglossal nerve stimulation is one of the mainstay treatments as an alternative for CPAP, we have a wide array of surgeries we can offer.”

In a recent episode of Cleveland Clinic’s Head and Neck Innovations podcast, Dr. Ramprasad provides insight on the latest innovations in surgical sleep. He delves into:

• How hypoglossal nerve therapy works
• What patients are candidates for hypoglossal nerve stimulator implantation
• Troubleshooting issues and options for patients that struggle with CPAP
• Soft tissue and skeletal surgical options for mild sleep apnea
• The role of drug-induced sleep endoscopy in patient evaluations

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Head and Neck Innovations episodes at clevelandclinic.org/podcasts/head-and-neck-innovations or wherever you get your podcasts.

Excerpt from the podcast

Podcast host Paul Bryson, MD, MBA: What are the steps or the qualifications to become a candidate to get a hypoglossal nerve stimulator? You mentioned CPAP intolerance, but there's probably more.

Vaibhav Ramprasad: Absolutely. So yeah, CPAP intolerance is sort of the main criteria in patients with obstructive sleep apnea. And I just want to emphasize also that while this is really exciting therapy, for patients that really are able to tolerate CPAP, CPAP is still sort of the gold standard for obstructive sleep apnea. We know we have a great body of evidence that suggests that it improves the daytime symptoms associated with sleep apnea, as well as some of the real cardiovascular risk factors that you see associated with it.

Obviously, there are patients that try CPAP and aren't able to tolerate it. And from a criteria standpoint, when the therapy first came out, there was a BMI cutoff of less than 35 and an AHI, which is the apnea-hypopnea index, between 15 and 65 per hour. That's actually been very recently – over the last couple months or so – liberalized. So, the BMI cutoff is now 40 or below, and the AHI is 15 to 100.

I think at this juncture though, from a practical standpoint, insurance companies have not really caught up to that new FDA guideline or the new FDA change in inclusion criteria. So, they're still relying on the older criteria. But I'm thinking hopefully soon it'll be liberalized from an insurance standpoint to be able to cover patients for the surgery as well.